Thursday, 13 April 2017

Bristol-Myers to license two of its drugs to Biogen, Roche

(Reuters) - Bristol-Myers Squibb Co said on Thursday it entered into a deal with Biogen Inc and Roche Holding AG to license two of its drugs for an upfront fee of $470 million.


Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)